Drug Trial Radar · NCT03596450
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,278
Actual
Start
Jul 13, 2018
Primary completion
Jun 9, 2022
Study completion Jun 9, 2023
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jul 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.
Conditions
- Diabetes Mellitus, Type 2
Interventions
SemaglutideDrug
Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
Standard of careDrug
Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No)Time frame: At year 1
Locations
181 sites in 2 countries. Site status is shown where the registry gives one.
American Clinical Trials
Buena Park, California
Endocrine Specialty Consultant Inc.
Burbank, California
FDRC
Costa Mesa, California
Bay Area Clinical Research
Dublin, California
Providence Medical Foundation
Fullerton, California
SC Clinical Research, Inc.
Garden Grove, California
SCKE Odyssey Medical Group
Laguna Hills, California
New Hope Consulting & Clinical Trials
Lancaster, California
OM Research LLC
Lancaster, California
Torrance Clin Res Inst, Inc.
Lomita, California
West Coast Endocrine, Inc.
Long Beach, California
Pacific Clinical Studies
Los Alamitos, California
Angel City Research
Los Angeles, California
University of Californ LA-UCLA
Los Angeles, California
Patel, Rahul
Manteca, California
Pacific Medical Center
Milpitas, California
Facey Medical Foundation
Mission Hills, California
Monterey Endocrine & Diabetes Institute, Inc
Monterey, California
Do-Eun Lee
Napa, California
Charles Andrews, MD
Newport Beach, California
Hoag Medical Group
Newport Beach, California
Adam B. Sherman D O Professional Corp.
Oxnard, California
Format Medical Research
Oxnard, California
Stanford Univ School of Med
Palo Alto, California
Posada, Juan
San Jose, California
Joselito C Cabaccan, MD
San Jose, California
Care Access Research Santa Clarita
Santa Clarita, California
Premier Medical Center, Inc.
Toluca Lake, California
Adnab Research/Prestige Care Physician
Torrance, California
Altura Centers For Health
Tulare, California
Tariq Javed, MD Inc.
Visalia, California
Endocrinology & Diabetes Specialists
Walnut Creek, California
PIH Health Physicians Endocrinology
Whittier, California
Optumcare Clinical Trials,LLC-Golden
Colorado Springs, Colorado
Delta Waves, Inc.
Colorado Springs, Colorado
University of Colorado Hospital
Denver, Colorado
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado
ProHealth Physicians/OptumCare
Bristol, Connecticut
Western Connecticut Health Network_Danbury
Danbury, Connecticut
Endocrine Associates of Connecticut
Hamden, Connecticut
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.